Body Pharm NAD+ 1000

The Body Pharm NAD+ 1000mg injection pen is a research-grade, pre-metered subcutaneous device delivering nicotinamide adenine dinucleotide in fixed 10, 20 or 30 mg actuations from a single 1000 mg cartridge, manufactured to EU GMP Annex 1 sterile-fill expectations and supplied in the United Kingdom for laboratory research use only.

Manual reconstitution from lyophilised vials typically introduces several-percent volume variability. Deviations of up to roughly 20% have been reported for sub-0.2 ml draws, according to a 2023 low-volume injection accuracy study. Meniscus reading, dead-space residue, and air bubbles all distort the final drawn volume. A pre-metered pen removes these variables by design. UK research buyers comparing NAD+ formats in 2026 increasingly specify pens over vials for titration studies in the 10–50 mg per-actuation band because of this precision gain.

Key Takeaways

• Pre-filled pen design eliminates reconstitution and syringe-draw variability, delivering ±3% dose accuracy across 10, 20 or 30 mg increments
• Multi-dose cartridge reduces needle entries into the drug reservoir compared with repeated vial punctures, lowering contamination risk over multi-week protocols
• 1000 mg per pen yields 100 actuations at 10 mg, 50 at 20 mg, or 33 at 30 mg; pricing is £149 per unit with free UK tracked delivery
• Published clinical NAD+ work sits at 500–750 mg per infusion; the 10–30 mg increment band on this pen sits outside current clinical trial ranges and should be treated as a research variable
• Batch-specific Certificate of Analysis, EU GMP Annex 1 fill standard, and ISO 13485:2016 device-level quality are included with every order

What Is the Body Pharm NAD+ 1000 Pen?

Body Pharm NAD+ 1000 is a pre-filled, multi-dose subcutaneous injection pen containing 1000 mg of nicotinamide adenine dinucleotide (CAS 53-84-9). It dispenses selectable 10, 20 or 30 mg increments per actuation for laboratory research use only. No reconstitution, no syringe draw, no vial transfer required.

NAD+ is a coenzyme present in every living cell. It is central to redox reactions, mitochondrial ATP production and sirtuin-mediated signalling. The pen encloses a sterile NAD+ solution in a sealed cartridge filled under EU GMP Annex 1 aseptic conditions. A dial mechanism metres the chosen dose into a fixed-volume actuation before subcutaneous delivery.

Format at a glance

• Active: nicotinamide adenine dinucleotide (NAD+), 1000 mg per cartridge
• Route: subcutaneous, fixed-needle pen
• Increments: 10 mg, 20 mg or 30 mg per click
• Reconstitution: none required (solution pre-filled)
• Classification: research-use-only, not a licensed medicine under MHRA

For protocol-level guidance on how researchers structure titration across those increments, see our full NAD+ dosing protocol, or compare against adjacent compounds in the longevity peptides range.

Full Product Specifications

The Body Pharm NAD+ 1000 pen contains 1000 mg of β-nicotinamide adenine dinucleotide (CAS 53-84-9) in a sealed, pre-filled subcutaneous device with selectable 10, 20 or 30 mg actuations. It is stored refrigerated at 2–8 °C and filled under EU GMP Annex 1 aseptic conditions. The table below reflects specifications verified as of Q1 2026.

The increment maths is deterministic: 1000 mg ÷ 30 mg leaves a 10 mg residual the dial will not dispense as a partial 30 mg actuation. Researchers planning titration schedules should cross-reference the full NAD+ dosing protocol or compare cartridge economics against other compounds in the longevity peptides range.

Pen Format vs Vial-and-Syringe: Why It Matters for Research

A pre-filled pen removes the two largest sources of dose error in NAD+ work: reconstitution and manual syringe draw. Lyophilised NAD+ vials require the researcher to add bacteriostatic water, swirl until fully dissolved, then draw a calculated volume into an insulin syringe. Each step introduces variance the pen format eliminates by design.

Dose precision

Manual syringe draws from small-volume vials typically deviate by 5–15% from intended volume. Error widens below 0.3 ml because of dead-space, meniscus reading, and air bubbles, per a 2023 review of low-volume injection accuracy. Trained operators in audited hospital pharmacy conditions can hold variance to roughly 5%, but that benchmark assumes controlled environments rather than bench reality. A dial-set actuation at 10, 20 or 30 mg removes the volumetric step entirely, the increment is mechanical, not estimated. Researchers concerned about dose reproducibility across multiple administrations will find the pen format more reliable than manual draw.

Contamination and storage after first use

A sealed multi-dose cartridge with a fixed needle reduces the number of needle entries into the drug reservoir compared with repeatedly drawing from a punctured vial septum. For protocols running daily or alternate-day administrations across weeks, that difference compounds. Both formats require 2–8 °C storage protected from light. The pen's in-use shelf life is governed by cartridge integrity rather than by how often a vial stopper has been pierced.

Which format suits which context

Vial-and-syringe still makes sense where a research protocol demands non-standard volumes (e.g. 7 mg, 12 mg) outside the pen's 10/20/30 mg dial, or where the workflow includes co-formulation with another compound at the point of draw. For fixed-increment titration schedules and repeat-dosing studies where dose reproducibility is the variable under control, the pen is the cleaner instrument. Researchers running structured titration should map their schedule against the full NAD+ dosing protocol before ordering.

NAD+ in Research: What the Evidence Shows (2022–2025)

Research on NAD+ between 2022 and 2025 clusters around three areas: cellular energy metabolism, sirtuin-mediated signalling, and oral precursor pharmacokinetics. No published clinical trial from 2024–2025 uses injectable NAD+ at 10–30 mg increments. Published infusion work sits at 500–750 mg per administration. That gap is worth flagging openly to research buyers before any protocol design, because the dose increments on this pen sit outside the published clinical range.

Energy metabolism and the NAD+/NADH ratio

NAD+ is a redox cofactor governing electron transfer in glycolysis, the TCA (tricarboxylic acid) cycle, and oxidative phosphorylation. A 2023 review on mitochondrial-derived peptides positioned MOTS-c as an upstream activator of AMPK (AMP-activated protein kinase) that raises the NAD+/NADH ratio and feeds into SIRT1 (Sirtuin 1) activity. A 2024 high-fat-diet mouse study reported MOTS-c treatment increasing tissue NAD+ alongside up-regulation of SIRT1 and PGC-1α (peroxisome proliferator-activated receptor gamma coactivator 1-alpha). A 2024 myotube study showed additive effects on oxygen-consumption rate when MOTS-c was combined with NAD+ precursor supplementation. Researchers running combination protocols often map these intersections against the longevity peptides range when designing cofactor studies.

Sirtuins and DNA repair

SIRT1 and SIRT3 (Sirtuin 3) are NAD+-dependent deacetylases implicated in mitochondrial biogenesis and stress response. The Rajman et al. 2018 framework is foundational but pre-2023 and should be treated as stale for current claims. The 2023 mitochondrial-peptide review updates the SIRT1/PGC-1α axis with more recent mechanistic detail.

Precursor comparison and route of administration

A 2023 randomised trial reported that oral NMN (Nicotinamide Mononucleotide) 600 mg raised whole-blood NAD+ and improved muscle insulin sensitivity in postmenopausal women versus placebo. No head-to-head human pharmacokinetic (PK) study from 2023–2025 compares subcutaneous NAD+ directly with oral NMN or NR (Nicotinamide Riboside). The mechanistic argument for the injectable route is first-pass bypass, not superior efficacy data. Researchers structuring titration should consult the full NAD+ dosing protocol for increment scheduling.

Quality, Sourcing & Batch Traceability

We fill, seal, and dose-validate every NAD+ 1000 pen to EU laboratory standard, consistent with EudraLex Volume 4 and the Annex 1 expectations for sterile injectable manufacture revised in 2022 and in force from 25 August 2023. Aseptic processing, container-closure integrity, and cleanroom classification follow the same framework that governs licensed sterile products in the EU, even though this pen is supplied as a research reagent rather than a licensed medicine.

Full traceability means three things in practice. Each pen carries a unique batch number printed on the pen and outer carton. A Certificate of Analysis (CoA) confirms identity and purity for that specific batch. Retained reference samples are held against the batch record. Device-level quality for the pen body and cartridge sits under ISO 13485:2016 conventions for medical device quality management systems.

Methodology, Body Pharm UK, Q1 2026 We fill, seal, and dose-validate every NAD+ 1000 pen to EU laboratory standard. Each batch is dose-tested across a minimum of 30 actuations per increment (10/20/30 mg) for fill accuracy within ±3%, ships with a Certificate of Analysis confirming purity and provenance, and retains two reference samples per batch for 24 months. Research teams can request batch documentation at point of order.

Procurement teams comparing specifications across our longevity peptides range can request the matching CoA before raising a purchase order, and cross-reference it against the increment schedule in the full NAD+ dosing protocol.

Ordering, Shipping & Returns in the UK

UK orders ship free via Royal Mail Tracked 24. Most addresses receive the NAD+ 1000 pen within 1–3 working days of dispatch. Body Pharm operates from within the United Kingdom, so domestic orders clear no customs and incur no import VAT on arrival.

Every parcel goes out in plain, unbranded outer packaging with no product or category markings on the exterior. The tracking number is emailed at dispatch. The pen is packed with cold-chain considerations appropriate to the consignment window.

Returns and research-use confirmation

Unused, unopened items can be returned within 14 days of receipt for a refund. Once a pen has been activated or its cartridge seal broken, it cannot be returned, in line with standard sterile-product handling. At checkout, buyers confirm the purchase is for laboratory research only and not for human administration, consistent with how UK suppliers of unscheduled injectable reagents position research-use-only stock under MHRA guidance.

For protocol detail before you order, the full NAD+ dosing protocol sets out the 10/20/30 mg increment schedule referenced on this page.

How to Dose NAD+ in a Research Protocol

The Body Pharm NAD+ 1000 pen offers three pre-metered increments per actuation: 10 mg, 20 mg, and 30 mg. Lower 10 mg settings suit fine titration work and tolerability mapping in early-phase research protocols. The 20 mg and 30 mg settings are typically selected for higher-throughput or acute-exposure designs where total cumulative dose per session matters more than micro-titration. The choice is a protocol-design decision, not a clinical recommendation: 10–30 mg per actuation is a device increment band, not a clinically validated dosing window in the 2024–2025 literature.

Subcutaneous administration bypasses hepatic first-pass metabolism. This is one reason injectable NAD+ is studied differently from oral NMN or NR precursors. Direct comparative pharmacokinetic data between subcutaneous NAD+ and oral precursors are not yet published for 2023–2025, so route selection remains a methodological variable researchers should record explicitly.

For the increment schedule, frequency mapping, and reconstitution notes, see the full NAD+ dosing protocol. NAD+ sits within our broader longevity peptides range for researchers designing multi-compound studies.

NAD+ and Longevity Research: Related Peptides

NAD+ sits within a wider longevity peptides range that researchers frequently stack for mechanistic overlap rather than redundancy. The compounds most often co-investigated alongside NAD+ are GHK-Cu, MOTS-c, and Tesamorelin, each addressing a distinct axis of cellular ageing biology.

GHK-Cu is studied for copper-dependent cellular repair and extracellular matrix signalling, adjacent to NAD+-driven sirtuin activity rather than overlapping with it. MOTS-c is a mitochondria-derived peptide with direct mechanistic relevance. 2023–2024 work positions MOTS-c within AMPK–SIRT1–PGC-1α signalling. One 2024 in-vitro myotube study reported synergistic increases in oxygen-consumption rate when MOTS-c was paired with boosted NAD+ availability. Protocol notes are in our MOTS-c dosing guide.

Tesamorelin targets the GH (growth hormone)/IGF-1 (insulin-like growth factor 1) axis and is typically researched in parallel rather than as a direct NAD+ interaction. See the Tesamorelin dosing guide for protocol context. Direct human co-administration data for NAD+ plus MOTS-c are not yet published as of 2025.

Frequently Asked Questions

Is NAD+ 1000 legal to buy in the UK for research?

NAD+ is not scheduled under the Misuse of Drugs Act 1971 or the Psychoactive Substances Act 2016. Body Pharm supplies the NAD+ 1000 pen for laboratory research and analytical purposes only, not for human consumption. This is consistent with MHRA guidance that distinguishes research-use-only reagents from unlicensed medicines promoted for self-administration.

What is the shelf life and storage requirement?

Store the sealed pen at 2–8 °C, protected from light. Unopened shelf life is 24 months. Once the pen is first pierced (first use), use it within 12 months. If refrigeration isn't available it stays stable at room temperature (up to 30 °C) for up to 30 days. The batch-specific Certificate of Analysis issued with each unit confirms the printed expiry for that lot.

Can the pen be used more than once?

Yes. The NAD+ 1000 pen is a multi-dose device delivering 10, 20 or 30 mg per actuation up to a 1000 mg cartridge total. It is capped between uses and kept refrigerated. Titration across multiple actuations is the intended use case. Protocol detail sits in our full NAD+ dosing protocol.

Is a Certificate of Analysis available?

A batch-specific CoA is available on request for every NAD+ 1000 pen shipped. It covers identity, purity, and fill-volume verification consistent with EU GMP Annex 1 fill-and-seal expectations. Quote the batch number printed on the pen when requesting.

What is the difference between NAD+ and NMN/NR?

NAD+ is the active coenzyme. NMN (Nicotinamide Mononucleotide) and NR (Nicotinamide Riboside) are oral precursors that the body converts to NAD+. A 2023 randomised trial of oral NMN 600 mg in postmenopausal women showed measurable rises in whole-blood NAD+. No 2023–2025 head-to-head human pharmacokinetic study compares subcutaneous NAD+ with oral NMN or NR. The pen sits within the wider longevity peptides range.

Order the NAD+ 1000 Pen

Order the Body Pharm NAD+ 1000mg injection pen at £149 with free UK Royal Mail tracked delivery, batch-specific CoA on request, and dispatch within one working day of order confirmation. Add the NAD+ 1000 pen to your order or request batch documentation before purchase by emailing support@bodypharm.co.uk.